Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states.
Funding Agency: National Institutes of Health
Deadline: January 7, 2023
For more information: http://grants.nih.gov/grants/guide/pa-files/PAR-20-082.html
Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)
This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states.
Funding Agency: National Institutes of Health
Deadline: January 7, 2023
For more information: http://grants.nih.gov/grants/guide/pa-files/PAR-20-055.html
Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites research grant applications that propose the preclinical development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in rodent and nonhuman primate brain and incorporation of pilot or clinical feasibility evaluation in pre-clinical studies and appropriate model development. Projects proposing clinical assessments of novel radioligands should respond to FOA PAR XX-XXX .
Funding Agency: National Institutes of Health
Deadline: January 7, 2023
For more information: http://grants.nih.gov/grants/guide/pa-files/PAR-20-037.html
Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) invites research grant applications that propose the development and evaluation of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain and the incorporation of, pilot or clinical feasibility evaluation from previously collected data in pre-clinical studies. These studies are expected to provide the requisite data needed to advance promising PET ligands for use in clinical research.
Funding Agency: National Institutes of Health
Deadline: January 7, 2023
For more information: http://grants.nih.gov/grants/guide/pa-files/PAR-20-038.html
NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)
This Trailblazer Award is an opportunity for New and Early Stage Investigators to pursue research programs of high interest to the NIBIB that integrate engineering and the physical sciences with the life and behavioral sciences. This FOA invites applications from researchers who are at the early stage of their independent careers or those who have not had substantial prior NIH funding. A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. Importantly, applicants are expected to propose research approaches for which there are minimal or no preliminary data. Preliminary Data: Trailblazer applications are meant to be exploratory, novel, and non-incremental. We encourage the submission of high-risk, high-reward projects. A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. However, if necessary, some minimal preliminary data is allowed. Minimal preliminary data are defined as material which the applicant has independently produced and not yet published in a peer-reviewed journal. Such evidence, if provided, should only be used to bolster and help establish the foundational premise for the Trailblazer application. All preliminary data must be clearly marked and limited to one-half page which may include one figure. Applications including data more than one-half page or more than one figure, will be considered noncompliant with the FOA instructions. Figures containing published data must include citations within the figure legend. Published data that is included in the research plan, biographical sketch or elsewhere in the application must be cited adjacent to each occurrence. Data that is published must be unambiguously identified as such within the application. References and data from widely-available preprints that have a Digital Object Identifier (DOI) are acceptable
Funding Agency: National Institutes of Health
Deadline: January 7, 2023
For more information: http://grants.nih.gov/grants/guide/pa-files/PAR-20-084.html
Center for Collaborative Research on Complex Generics (U18) Clinical Trials Optional
Background: The FDA’s Office of Generic Drugs (OGD) implements the generic drug research program under the Generic Drug User Fee Amendments (GDUFA) in part by collaborating externally with various institutions. The GDUFA research program supports the development of new tools for FDA to evaluate generic drug equivalence and for industry to efficiently develop new generic products. In the re-authorization of GDUFA in 2017 (GDUFA II), FDA made a commitment to assist industry in the submission of an ANDA for a complex drug product by making improvements in the process for development of product-specific guidances and conduct of pre-ANDA meetings for complex products. As described in the GDUFA II Commitment Letter (https://www.fda.gov/media/101052/download ), complex products generally consist of: (1) products with complex active ingredients, complex formulations, complex routes of delivery, or complex dosage forms, (2) complex drug-device combination products, and (3) other products where complexity or uncertainty concerning the approval pathway or possible alternative approach would benefit from early scientific engagement. The development of guidances and recommendations (communicated through product-specific guidances and pre-ANDA meetings) require FDA to continually improve a strong scientific research program related to complex generic drug products. Each year, OGD posts research priorities for generic drugs on its webpage at: https://www.fda.gov/drugs/generic-drugs/generic-drugs-priorities-projects. As yearly research priorities for generic drugs are identified, FDA recognizes the need for improved collaborations with the generic industry to successfully address scientific gaps that may present barriers to generic product development and/or ANDA review. Therefore, the FDA is announcing this FOA to establish a Center for Research on Complex Generics with the goals of providing the following: (1) facilitation of engagement with generic industry to encourage participation in complex generics research, (2) coordination of research projects pertaining to complex generics with the generic drug industry, and (3) coordination of training, workshops, and other educational activities pertaining to complex generic drug research. These efforts will enable FDA to establish enhanced research collaborations with the generic industry to further the FDA’s mission of increasing access to safe and effective generic drugs. This new center will complement FDA’s existing regulatory science programs through its specific focus as a hub for coordination and engagement with the generic industry.
Program Characteristics: Collaborative interactions to stimulate generic drug research engagement from the generic drug industry and accelerate progress in areas of high priority to OGD and the generic drug industry. Collaborative interactions may include: Scientific exchanges such as a visiting scientist program. FDA staff may visit the Center or a partner site to provide lectures and/or participate in workshops, spend time learning about new technologies or how to use new instrumentation and meet with program directors and interested scientific staff. Reciprocally, Center members may visit FDA to provide lectures and/or participate in workshops, visit FDA laboratories, and meet with FDA staff. These discussions may foster new collaborations/interactions with Center members and FDA. Industry scientists also may visit the Center to learn about new technology and aid the Center in developing research proposals that address scientific challenges in the generic drug industry. Such visits will be conducted consistent with all applicable laws, regulations and policies, to minimize conflicts of interest, or the appearance of conflicts of interest. In addition, any non-public information may only be shared as authorized by law and regulation. Workshops on generic drug research. These workshops should engage FDA, the Center and its members, the generic drug industry and the public. These workshops may be co-sponsored with the FDA, consistent with applicable policies regarding co-sponsorships. Scientific and educational workshops in partnership with FDA may be proposed for horizon scanning for emerging fields or trends in generic drug research to bring relevant stakeholders together and to accelerate understanding of different fields. Applicants need to demonstrate their ability to accomplish the collaborative interactions described above, as well as propose other types of interactions that would further engagement with the public, in particular, with the generic industry. Infrastructure to support core program for the Center. Applicants must describe the proposed organizational structure to establish and support collaborations with other entities and individual investigators. Cutting-edge scientific research in analytical methods, modeling and simulation, formulation science, clinical and pre-clinical development, and other areas pertaining to generic drug research. Applicants must demonstrate partnerships with scientific investigators who have expertise in these areas and understand the goals of the generic drug research program. Applicants should also demonstrate the ability to engage effectively with the generic drug industry. As noted on page 16, below, when research resources have been developed with FDA funds and the associated research findings published, those findings must be made readily available to the scientific community.
Funding Agency: Food and Drug Administration
Deadline: April 13, 2020
Amount: $5,000,000
For more information: https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-20-007.html
BLM-CO: Fuels Management & Community Fire Assistance
The Colorado State office of the Bureau of Land Management’s (BLM) Fuels Management and Community Fire Assistance program uses a risk-based approach that supports the National Cohesive Wildland Fire Management Strategy goals of restoring and maintaining fire resilient landscapes, creating fire-adapted communities and responding to wildfire. The Colorado State Office of the BLM has an opportunity to work with partner organizations to assist with fuels management and community fire assistance program activities to reduce the risk and impact of catastrophic wildfires to local communities through coordination, reducing the amount of hazardous fuels, and furthering the education of landowners about wildfire prevention and mitigation.For more information on how to apply, please visit www.grants.gov to download a full announcement, instructions, and application package.
Funding Agency: Bureau of Land Management
Deadline: March 13, 2020
Amount: $50,000
For more information: Go to grants.gov and search opportunity #L20AS00034
FY2020 High Priority-Commercial Motor Vehicle Grant Program (HP-CMV)
The U.S. Department of Transportation’s Federal Motor Carrier Safety Administration (FMCSA) announces the Fiscal Year (FY) 2020 High Priority-Commercial Motor Vehicle (HP-CMV) program Notice of Funding Opportunity (NOFO) to solicit applications from eligible entities to support the HP-CMV program activities.As the lead government agency responsible for the regulation and safety oversight of commercial motor vehicles (CMV), FMCSA may award HP-CMV funds to support innovative and impactful projects that advance its mission to reduce crashes, injuries, and fatalities involving large trucks and buses. Funding is available for the support of enforcement projects that improve safety and compliance with FMCSA’s regulations for projects that are national in scope, increase public awareness and education, demonstrate new technologies, and reduce the number/rate of CMV crashes.These activities are supported in alignment with the U.S. Department of Transportation’s strategic goals of: SAFETY: Reduce transportation-related fatalities and serious injuries across the transportation system. INFRASTRUCTURE: Invest in infrastructure to ensure safety, mobility and accessibility and to stimulate economic growth, productivity and competitiveness for American workers and businesses. INNOVATION: Lead in the development and deployment of innovative practices and technologies that improve the safety and performance of the Nation’s transportation system. ACCOUNTABILITY: Serve the Nation with reduced regulatory burden and greater efficiency, effectiveness and accountability.
Funding Agency: DOT/Federal Motor Carrier Safety Administration
Deadline: February 21, 2020
Amount: $2,000,000
For more information: https://www.grantsolutions.gov/gs/preaward/previewPublicAnnouncement.do?id=65299
FY2020 Commercial Motor Vehicle Operator Safety Training Grant Program
The CMVOST grant program supports the Secretary’s strategic goals. The purpose is to expand the number of commercial driver’s license (CDL) holders possessing enhanced operator safety training to help reduce the severity and number of crashes on U.S. roads involving CMVs. Additionally, this grant seeks to assist current or former members of the U.S. Armed Forces, including National Guard and Reservists, obtain a CDL. This NOFO provides important information about the FY 2020 CMVOST program activities/projects and guidance related to preparing and submitting a grant application.CMVOST grant funds are awarded through a competitive grant process. No assurance of funding is implied, nor should it be inferred.
Funding Agency: DOT/Federal Motor Carrier Safety Administration
Deadline: February 24, 2020
Amount: $100,000
For more information: https://www.grantsolutions.gov/gs/preaward/previewPublicAnnouncement.do?id=65302
2020 U.S. Elections Programming
The Public Affairs Section of the U.S. Embassy in Singapore announces an open competition for proposals to design, plan, and implement a multi-event public diplomacy initiative to foster greater understanding of U.S. elections among Singaporeans. Themes should be educational in nature and may focus on a range of topics, including presidential campaigns, debates, grassroots advocacy, civil society participation, primaries and caucuses, political parties, the electoral college, political polling, elections reporting, media literacy, combating disinformation, voting processes, and peaceful transitions of power. Programs should focus on promoting mutual understanding between Americans and Singaporeans through a dynamic cultural and informational exchange. Activities may not be partisan in nature.
Funding Agency: US Mission to Singapore
Deadline: February 28, 2020
Amount: $75,000
For more information: https://sg.usembassy.gov/embassy/singapore/notice-funding-opportunity/2020-us-elections-programming/
2020 Olympics Programming
The Public Affairs Section of the U.S. Embassy in Singapore announces an open competition for proposals to design, plan, and implement a multi-event, multi-platform Olympics-themed public diplomacy initiative in Singapore around the 2020 Summer Olympic and Paralympic Games. Programs will leverage a mutual passion for sports, international competition, and shared values like sportsmanship; teamwork; fairness and transparency; and diversity and inclusion to build mutual understanding between Singaporeans and Americans.
Funding Agency: US Mission to Singapore
Deadline: February 28, 2020
Amount: $75,000
For more information: https://sg.usembassy.gov/embassy/singapore/notice-funding-opportunity/2020-olympics-programming/
Enhancing Regulatory Science for Advancing Pharmaceutical Quality and Manufacturing (U01) Clinical Trials Optional
Background: FDA regulates pharmaceutical drug products to ensure a continuous supply of high quality drugs in the United States. In regulating the pharmaceutical manufacturing sector, new technologies can improve drug quality, address shortages of medicines, and lower drug costs. To help achieve this, FDA encourages development and adoption of emerging manufacturing technology to modernize pharmaceutical manufacturing. Advanced manufacturing holds great promise for improving the American market for drugs and biologicals and, results in a more robust manufacturing process with fewer interruptions in production, fewer product failures (before or after distribution), and greater assurance that the drug products manufactured in any given period of time will provide the expected clinical performance. In other words, encouraging the development and adoption of emerging manufacturing technologies may lead to improved manufacturing, and therefore improved product quality and availability throughout a product’s lifecycle. The complexity of drug products has been increasing over the years, in part due to, the increasing number of poorly soluble drugs, targeted drug delivery to traditionally un-druggable sites, and increasing focus on personalized and precision medicine. In the realm of drug products, complexity may arise from the active ingredient, the formulation, the dosage form, etc. In order to prepare for the increase in complex products, the Office of Pharmaceutical Quality is considering best practices and paths forward in the risk-based quality assessment of complex drug products. While the development of emerging technology is critical to modernizing pharmaceutical manufacturing and improving quality, FDA also recognizes that the implementation of emerging technology could present challenges to both industry and FDA. By the very nature of an approach being new or innovative in pharmaceutical industry, a limited knowledge and experiential base about the technology may exist. This program aims to address knowledge and experience gaps identified for emerging manufacturing technology and support the development and adoption of such technology in the pharmaceutical sector.
Project Objectives: The goal of this program is to support the advancement of regulatory science that can (1) facilitate the implementation and the assessment of emerging manufacturing technology in the pharmaceutical sector; (2) expand the knowledge base related to complex products and formulation development, analysis, and manufacturing control to advance risk-based quality assessment of new and generic drug products. Identified emerging technologies should be sufficiently developed and likely ready for industrial implementation for the purpose of product quality enhancement. The results and knowledge developed in this program can be utilized by industry, academia, and industry to support the implementation of the identified emerging technologies and to ensure that FDA regulatory policies reflect state-of-the-art manufacturing science. Specifically, the expected project outcomes should enable (1) developing tools and approaches for risk-based quality assessment, (2) establishing science-based quality standards and policies, and/or (3) providing training tools for both the industry and/or the regulatory bodies for the identified emerging technology. Potential research projects could include those that focus on characterizing complex drug substances (including botanical drug substances) and complex drug product dosage forms. Projects could include related control strategies to ensure the product quality, especially those which can help solve potential regulatory questions related to drug quality. Specific topics could relate to the following: Appropriate analytical methods for complex drug substances or products; In-process controls during manufacturing processes to ensure product quality; Raw material quality control. NOTE: Proposals should clearly describe the potential impacts of the proposed technology on readiness for broad implementation in pharmaceutical industry, control strategy, and/or regulatory evaluation for complex drug substances and complex drug product dosage forms.
Funding Agency: Food and Drug Administration
Deadline: April 10, 2020
Amount: $5,000,000
For more information: https://grants.nih.gov/grants/guide/pa-files/PAR-20-083.html
Digital, Limited Interaction Trials and Epidemiology (D-LITE): Targeting HIV Incidence in the United States (U01 Clinical Trial Required)
The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to conduct large-scale digital clinical trials to test whether digitally-delivered HIV prevention interventions can reduce HIV incidence among U.S. men who have sex with men (MSM) and/or transgender women and men. The major goal is to support investigators who will use innovative electronic methods to recruit and retain large samples of persons at high risk of HIV infections, conduct digitally-delivered interventions that promote HIV risk reduction and pre-exposure prophylaxis (PrEP) use, and assess the resulting impact on HIV incidence through mailed HIV test kits or other remote means.
Funding Agency: National Institutes of Health
Deadline: March 20, 2020
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-19-067.html
Pilot Centers for Precision Disease Modeling (U54) (Clinical Trials Not Allowed)
This Funding Opportunity Announcement (FOA) invites U54 cooperative agreement applications for Pilot Centers for Precision Disease Modeling. The goal of the Centers is to support collaborative research projects that link current personalized medicine efforts in human subjects with advances in animal genomics and technologies for genetic manipulation and creation of interspecies somatic hybrids. Functionally linking these areas of research will produce programs to enhance the predictive value of preclinical studies based on the use of precision animal models. Centers will create a process by which the research community can nominate unique human genomic variants for a cost effective high-throughput testing in an animal model pipeline. After validation of the expected gene editing, the Centers will establish assays to conduct comprehensive functional and phenotyping analysis to evaluate disease-causing variants. An important mission of the Centers will be the creation and distribution of precision animal model resources and related services to the biomedical community. Therefore, Centers will establish pipelines for preclinical scientific discovery, disease modeling, and development of interventions based on innovative animal models. Because these preclinical pipelines eventually will be an integral part of diagnostics, care and therapeutic treatment of patients, Centers should demonstrate how they intend to achieve this. Even though the Centers will work on a limited number of focused projects, it is expected that the program and pipeline(s) developed by the Center will maintain multifaceted research activities to build core model systems that can be adjusted as required to accommodate a broad spectrum of diseases.
Funding Agency: National Institutes of Health
Deadline: March 24, 2020
Amount: $1,250,000
For more information: http://grants.nih.gov/grants/guide/pa-files/PAR-20-085.html
Animal and Biological Material Resource Centers (P40) (Clinical Trials Not-Allowed)
This FOA encourages grant applications for national Animal and Biological Material Resource Centers. These Centers provide support for special colonies of laboratory animals, as well as other resources such as informatics tools, reagents, cultures (cells, tissues, and organs) and genetic stocks that serve the biomedical research community in a variety of research areas on a local, regional, and national basis. The important mission of the projects described by this FOA is to provide research resources, which are facilitating the optimization and enhancement of scientific rigor, transparency and experimental reproducibility of biomedical research. Proposed Animal and Biological Material Resource Centers must have broad application to multiple NIH Institutes or Centers (ICs) to align with the ORIPs trans-NIH mission (https://orip.nih.gov/about-orip). This funding opportunity is designed to support both continuation of existing resources and to develop new ones when appropriate. Prior to preparing an application, all applicants are strongly encouraged to consult with Scientific/Research staff to be advised on appropriateness of the intended resource plans for this program, competitiveness of a potential application, and ORIP’s program priorities.
Funding Agency: National Institutes of Health
Deadline: January 7, 2023
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-002.html
Rehabilitation Engineering Research Centers (RERC) Program: RERC on Rehabilitation Strategies, Techniques, and Interventions
The purpose of the RERC program is to improve the effectiveness of services authorized under the Rehabilitation Act by conducting advanced engineering research on and development of innovative technologies that are designed to solve particular rehabilitation problems or to remove environmental barriers. RERCs also demonstrate and evaluate such technologies, facilitate service delivery system changes, stimulate the production and distribution of new technologies and equipment in the private sector, and provide training opportunities.
Field-Initiated RERC on Rehabilitation Strategies, Techniques, and Interventions: In this area, NIDILRR seeks to fund research and development that leads to rehabilitation practices and services that improve the health, and the physical, cognitive, sensory, and communication abilities, of individuals with a wide range of disabling conditions. Rehabilitation engineering in this area should result in new or improved products, devices, and technological advances that enhance rehabilitation services in clinical or community settings.
Funding Agency: Administration for Community Living
Deadline: March 9, 2020
Amount: $925,000
For more information: https://acl.gov/grants/applying-grants
Conducting Public Health Research in South America
The purpose of this NOFO is to:Conduct and monitor epidemiologic and laboratory-based projects, surveillance, and research of important diseases in South America (Brazil, Bolivia, Argentina, Chile, Peru, Uruguay, Paraguay, Venezuela, Guyana, Suriname, and Ecuador) including, but not limited to, activities to address acute febrile illness, antimicrobial resistance and hospital acquired infections, respiratory infections and influenza, enteric illnesses, and other public health threats of local importance; and,Incorporate the results of these public health activities into operational disease detection, prevention, and response or control programs in South America, strengthen public health capacity as outlined in the Global Health Security Agenda, and disseminate findings across the region, with partners, and globally.
Funding Agency: Centers for Disease Control and Prevention – ERA
Deadline: March 9, 2020
Amount: $5,000,000
For more information: Go to grants.gov and search opportunity #RFA-GH-20-005